Outlook Therapeutics CFO Kenyon acquires 101,010 shares

[
Outlook Therapeutics CFO Kenyon acquires 101,010 shares
[og_img]
https://www.investing.com/news/insider-trading-news/outlook-therapeutics-cfo-kenyon-acquires-101010-shares-93CH-4861649

Investing.com

CXMT Overtakes Tencent as AI Memory Demand Drives Chip Rally

‘There’s no realistic chance all of that content will get remastered from scratch’: Dolby Vision 2 will come to more titles than you might...

CXMT Overtakes Tencent as AI Memory Demand Drives Chip Rally

Singapore Is Literally Training People to Get Scammed

Ex-Israeli Intelligence Official: Shockwaves of Trump’s “Take Over Gaza” Heard, Felt Across Region

What UK political parties are promising in the 2019 general election

Otto Warmbier’s parents want North Korea to suffer for their son’s death

Could a ‘youthquake’ cause Boris Johnson to lose the general election?

Emmy Nominees Head To Final Emmy Campaign Stops Of 2026

Adam Scott’s Daughter Watched Office Audition as What Not to Do

Disney Cursed Love Romantasy Webcomics to Launch on Webtoon

Married at First Sight’s Ryan De Nino Dead at 40

Crowdstrike president and CEO George Kurtz sells $4.46 million in shares

JPMorgan debanked Polymarket last year over regulatory concerns, source says

TKO director Nick Khan sells $1.89m in company stock

Universal Technical Institute director DeVincenzi buys $25,945 in shares

The YouTuber who has become one of Gen Z’s most beloved celebrities

26 last-minute holiday gifts that are still thoughtful and unique

Practicing gratitude regularly can make you less stressed and sleep better

8 things millennials wish you would just stop getting them for the holidays

Outlook Therapeutics CFO Kenyon acquires 101,010 shares

Crowdstrike president and CEO George Kurtz sells $4.46 million in shares

CXMT Overtakes Tencent as AI Memory Demand Drives Chip Rally

Emmy Nominees Head To Final Emmy Campaign Stops Of 2026

JPMorgan debanked Polymarket last year over regulatory concerns, source says

Leave a reply Cancel reply